Literature DB >> 18715916

Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice.

Daryl S Spinner1, In Soo Cho, Seung Yong Park, Jae Il Kim, Harry C Meeker, Xuemin Ye, Giuseppe Lafauci, Daniel J Kerr, Michael J Flory, Bo Sook Kim, Regina B Kascsak, Thomas Wisniewski, William R Levis, Georgia B Schuller-Levis, Richard I Carp, Eunkyue Park, Richard J Kascsak.   

Abstract

Prion diseases such as scrapie involve the accumulation of disease-specific prion protein, PrP(Sc), in the brain. Toll-like receptors (TLRs) are a family of proteins that recognize microbial constituents and are central players in host innate immune responses. The TLR9 agonist unmethylated CpG DNA was shown to prolong the scrapie incubation period in mice, suggesting that innate immune activation interferes with prion disease progression. Thus, it was predicted that ablation of TLR signaling would result in accelerated pathogenesis. C3H/HeJ (Tlr4(Lps-d)) mice, which possess a mutation in the TLR4 intracellular domain preventing TLR4 signaling, and strain-matched wild-type control (C3H/HeOuJ) mice were infected intracerebrally or intraperitoneally with various doses of scrapie inoculum. Incubation periods were significantly shortened in C3H/HeJ compared with C3H/HeOuJ mice, regardless of the route of infection or dose administered. At the clinical phase of disease, brain PrP(Sc) levels in the two strains of mice showed no significant differences by Western blotting. In addition, compared with macrophages from C3H/HeOuJ mice, those from C3H/HeJ mice were unresponsive to fibrillogenic PrP peptides (PrP residues 106 to 126 [PrP(106-126)] and PrP(118-135)) and the TLR4 agonist lipopolysaccharide but not to the TLR2 agonist zymosan, as measured by cytokine production. These data confirm that innate immune activation via TLR signaling interferes with scrapie infection. Furthermore, the results also suggest that the scrapie pathogen, or a component(s) thereof, is capable of stimulating an innate immune response that is active in the central nervous system, since C3H/HeJ mice, which lack the response, exhibit shortened incubation periods following both intraperitoneal and intracerebral infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715916      PMCID: PMC2573175          DOI: 10.1128/JVI.00522-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

Review 1.  Toll-like receptors in innate immunity.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  Int Immunol       Date:  2005-01       Impact factor: 4.823

2.  Simple and specific detection of abnormal prion protein by a magnetic bead-based immunoassay coupled with laser-induced fluorescence spectrofluorometry.

Authors:  Jae-Il Kim; Chuanhua Wang; Salomon Kuizon; Jiliu Xu; Denis Barengolts; Perry C Gray; Richard Rubenstein
Journal:  J Neuroimmunol       Date:  2005-01       Impact factor: 3.478

3.  Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process.

Authors:  Clive Bate; Ronald Boshuizen; Alun Williams
Journal:  J Neuroimmunol       Date:  2005-10-11       Impact factor: 3.478

Review 4.  Mutations in TLR4 signaling that lead to increased susceptibility to infection in humans: an overview.

Authors:  Stefanie N Vogel; Agnes A Awomoyi; Prasad Rallabhandi; Andrei E Medvedev
Journal:  J Endotoxin Res       Date:  2005

5.  Detoxified lipopolysaccharide reduces microglial cell killing of prion-infected neurons.

Authors:  Clive Bate; Alun Williams
Journal:  Neuroreport       Date:  2004-12-22       Impact factor: 1.837

6.  Prion clearance in bigenic mice.

Authors:  Jiri G Safar; Stephen J DeArmond; Katarzyna Kociuba; Camille Deering; Svetlana Didorenko; Essia Bouzamondo-Bernstein; Stanley B Prusiner; Patrick Tremblay
Journal:  J Gen Virol       Date:  2005-10       Impact factor: 3.891

7.  Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients.

Authors:  Milan Fiala; Justin Lin; John Ringman; Vali Kermani-Arab; George Tsao; Amish Patel; Albert S Lossinsky; Michael C Graves; Andrew Gustavson; James Sayre; Emanuela Sofroni; Tatiana Suarez; Francesco Chiappelli; George Bernard
Journal:  J Alzheimers Dis       Date:  2005-06       Impact factor: 4.472

8.  Adenovirus RIDalphabeta complex inhibits lipopolysaccharide signaling without altering TLR4 cell surface expression.

Authors:  Fernando Delgado-Lopez; Marshall S Horwitz
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

9.  Generation of a monoclonal antibody agonist to toll-like receptor 4.

Authors:  S B Cohen; C Gaskins; M S Nasoff
Journal:  Hybridoma (Larchmt)       Date:  2005-02

10.  Skin-derived dendritic cells acquire and degrade the scrapie agent following in vitro exposure.

Authors:  Joanne Mohan; John Hopkins; Neil A Mabbott
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

View more
  31 in total

Review 1.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Altered lymphocyte proliferation and innate immune function in scrapie 139A- and ME7-infected mice.

Authors:  In Soo Cho; Daryl S Spinner; Richard J Kascsak; H Cliff Meeker; Bo Sook Kim; Seung Yong Park; Georgia Schuller-Levis; Eunkyue Park
Journal:  Viral Immunol       Date:  2013-05-08       Impact factor: 2.257

3.  Protective role of interferon regulatory factor 3-mediated signaling against prion infection.

Authors:  Daisuke Ishibashi; Ryuichiro Atarashi; Takayuki Fuse; Takehiro Nakagaki; Naohiro Yamaguchi; Katsuya Satoh; Kenya Honda; Noriyuki Nishida
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 4.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 5.  A clear and present danger: endogenous ligands of Toll-like receptors.

Authors:  Jacob A Sloane; Daina Blitz; Zachary Margolin; Timothy Vartanian
Journal:  Neuromolecular Med       Date:  2009-10-14       Impact factor: 3.843

6.  Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain-dependent manner.

Authors:  Jan Kranich; Nike Julia Krautler; Jeppe Falsig; Boris Ballmer; Shulei Li; Gregor Hutter; Petra Schwarz; Rita Moos; Christian Julius; Gino Miele; Adriano Aguzzi
Journal:  J Exp Med       Date:  2010-09-13       Impact factor: 14.307

Review 7.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

8.  Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels.

Authors:  Déborah Tribouillard-Tanvier; James F Striebel; Karin E Peterson; Bruce Chesebro
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

9.  Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2.

Authors:  C Dirk Keene; Rubens Chang; Christina Stephen; Mary Nivison; Samuel E Nutt; Amy Look; Richard M Breyer; Phillip J Horner; Robert Hevner; Thomas J Montine
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

10.  NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity.

Authors:  Iva Hafner-Bratkovič; Mojca Benčina; Katherine A Fitzgerald; Douglas Golenbock; Roman Jerala
Journal:  Cell Mol Life Sci       Date:  2012-08-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.